TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Surgeons Operating On Patient

SAVR linked to higher 10-year survival rate than TAVR for low-risk patients

TAVR patients in this study were treated with early-generation devices that have since been updated, but researchers still believe their data are relevant to today's care teams.

Redo TAVR: A 26-mm Sapien 3 device (Edwards Lifesciences) implanted within a 29-mm CoreValve device (Medtronic). Image courtesy of EuroIntervention.

Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

Thumbnail

Treating younger patients with TAVR increases risk of death

Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely. 

Newsweek ranked the 50 best heart hospitals in the world

Cardiologist demand is on the rise—can hospitals keep up?

Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind. 

Thumbnail

Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years

SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.

Philippe Genereux explains how EARLY TAVR will help raise awareness for undertreatment of TAVR.

New data put a spotlight on troubling TAVR trends

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.

Philippe Genereux, MD, explains the details of the EARLY TAVR trial, which compared early interventions vs. waiting in patients with asymptomatic severe aortic stenosis.

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

A Da Vinci Xi robot from California-based Intuitive Surgical. Researchers used these robotic surgical systems to help guide AVR in low- and intermediate-risk patients who presented with severe AS.

Robotic aortic valve replacement may offer certain benefits over TAVR

Robotic-assisted aortic valve surgery may be a safe, effective alternative to TAVR when treating low- and intermediate-risk patients. A new analysis in The Annals of Thoracic Surgery explored this topic at length.

Displaying 17 - 24 of 419
Design by Adaptive Theme